Say you’ve tried the usual routes, your doctor has a three-week wait, insurance is a maze, and you’ve already seen the Ozempic ads. You know compounded semaglutide exists, you’ve heard tirzepatide is stronger, and now you’re staring at a dozen websites that all look roughly the same. Which one do you actually pay?
This guide lays out the decision criteria first, then maps seven providers onto each one. No filler.
How to Actually Compare These Services
Before reading any brand entry, decide which of these matters most to you:
- Price per month (cash, all-in): What hits your card, including any “platform fee” billed separately from medication.
- Pharmacy transparency: Can you verify the compounding pharmacy by name, state, and compliance standard? Or is it just “our licensed pharmacy partner”?
- Speed: How fast does a physician actually review your intake, and how fast does medication ship?
- Monitoring depth: Some programs include check-ins, labs, and coaching. Others are prescription-only. Neither is wrong, but they suit different people.
- State availability: A few providers skip 3-5 states. Worth confirming before you fill out an intake form.
- Branded vs. compounded: The March 2026 Novo Nordisk settlement pushed several major platforms to exit compounded semaglutide entirely. Know what you’re getting.
With those filters in mind, here are seven providers worth a close look.
1. HealthRX
Compounded semaglutide from $99/month, compounded tirzepatide from $149/month, free overnight shipping to all 50 states. That price-to-reach combination is genuinely hard to beat.
The pharmacy is Manifest Pharmacy in Greer, South Carolina, a 503A facility operating under USP-797 standards with lot-tracked batches from production through delivery. That’s a named, verifiable operation, not a vague “partner lab.” HealthRX also holds LegitScript certification (cert 50087439), and a U.S. board-certified physician reviews each intake within about 24 hours.
Medication is compounded, meaning it is not FDA-approved as a final product. The clinical trial numbers HealthRX references are from the original research: roughly 15% average body weight reduction over 68 weeks for semaglutide (STEP 1 trial) and about 21% over 72 weeks for tirzepatide (SURMOUNT-1). Those are trial outcomes, not guarantees.
Good fit for: cash-pay buyers who want low entry pricing, fast physician review, and a pharmacy they can actually look up.
2. FormBlends
FormBlends runs the same basic telehealth model but separates itself with published per-product purity data. Each batch comes with HPLC purity percentages, mass spec identity confirmation, and endotoxin sterility results. Most GLP-1 telehealth companies don’t show you that documentation at all.
Pricing is higher than HealthRX: compounded semaglutide around $299 per vial, tirzepatide around $349. It ships to 47 states, not all 50. The tradeoff is that you get lab-level transparency that most cash-pay programs skip entirely.
FormBlends also carries a wider peptide catalog covering recovery, longevity, and cognitive-health compounds under the same clinician-oversight model. If GLP-1 is just one piece of a broader protocol you’re building, that matters.
Good fit for: buyers who want documented purity testing, or who want GLP-1s plus other peptides without switching providers, and don’t mind paying more for it.
3. Mochi Health
Board-certified obesity-medicine physicians, not just general practitioners. Compounded semaglutide runs about $99/month and tirzepatide about $199/month. The program includes more structured follow-up than most bare-bones telehealth options, which suits people who want clinical oversight baked in rather than bolted on.
4. Hims & Hers
Once the March 2026 Novo settlement took effect, the company dropped compounded semaglutide and shifted its catalog to brand-name options. Injectable Wegovy sits around $299/month, oral semaglutide around $249, Zepbound around $399. With insurance plus a manufacturer savings card, some patients bring that down to $0-25/month. The brand recognition is high and the app experience is polished. Best option if you have insurance that will actually process the claim.
5. Ro Body
Ro charges roughly $39 for the first month, then $74-149/month for the platform, with medication billed separately. It has a dedicated prior-authorization team and accepts insurance for branded medications. Slower to get started than cash-pay services, but the insurance support is among the more developed in the space.
6. Henry Meds
Cash-pay compounded GLP-1s, $179-249 for month one, with shipping in 24-72 hours. Lighter on ongoing monitoring compared to Mochi or Calibrate. Works well for someone who wants fast access and doesn’t need hand-holding between doses.
7. Calibrate
A roughly 12-month program where the coaching and curriculum cost is separate from medication. Expensive when you total it up, but Calibrate’s model is built around behavior change alongside the medication, not just the prescription. If accountability and structured habit-building are what you’re actually missing, this structure fits better than a pure prescription service.
A Few Things to Confirm Before You Buy
Compounded medications are not FDA-approved finished products, regardless of which provider you use. The FDA issued warning letters to more than 30 telehealth and compounding operations in early 2026, so confirming your pharmacy’s compliance credentials before ordering is reasonable, not paranoid. Prices shift, state availability changes, and what a company offers today may look different in six months. Verify current pricing directly with each provider.
Common Questions
Does the March 2026 Novo Nordisk settlement mean compounded semaglutide is now illegal everywhere?
Not across the board. The settlement changed what major retail telehealth platforms like Hims & Hers would offer, but 503A compounding pharmacies can still fill compounded semaglutide under a valid prescription for individual patients in many states. The regulatory situation is fluid, so confirm your provider’s current status before ordering.
How do you actually verify that a compounding pharmacy is legitimate before you pay?
Start with two things: the pharmacy’s name and state license, which you can cross-check against your state board of pharmacy, and any LegitScript certification number. HealthRX publishes cert 50087439 and names Manifest Pharmacy in South Carolina. That’s the standard worth holding other providers to.
Is tirzepatide actually worth the higher monthly cost compared to semaglutide for most people?
The trial data shows a real difference: roughly 21% average body weight reduction over 72 weeks for tirzepatide (SURMOUNT-1) versus about 15% over 68 weeks for semaglutide (STEP 1). Whether that gap justifies $50-100 more per month depends on your starting weight, your response to the lower dose, and your budget. Individual results vary considerably.
Which of these seven services makes the most sense if you want to use insurance rather than pay cash?
Hims & Hers and Ro Body are the clearest answers here. Ro has a dedicated prior-authorization team and accepts insurance for branded medications. Hims & Hers shifted entirely to branded options like Wegovy and Zepbound after March 2026, and some patients bring costs down to near zero with insurance plus manufacturer savings cards.
What’s the real difference between a program like Calibrate and a straightforward prescription service like Henry Meds?
Henry Meds gets you medication fast with minimal ongoing contact. Calibrate wraps a roughly 12-month coaching curriculum around the prescription, at a higher total cost, with the premise that behavior change alongside medication produces better long-term outcomes. If you’re disciplined and self-directed, Henry Meds is cheaper. If structure and accountability are what you’re actually short on, Calibrate’s model addresses that directly.
Sources
- FDA compounding oversight and 503A pharmacy standards: fda.gov
- SURMOUNT-1 tirzepatide trial (Jastreboff et al., 2022), published in *The New England Journal of Medicine*
- STEP 1 semaglutide trial (Wilding et al., 2021), published in *The New England Journal of Medicine*
- Novo Nordisk settlement details, March 2026: public company and FDA communications
- LegitScript pharmacy certification registry: legitscript.com
